Becker M D, Lortz S, Flückiger B, Luginbuehl V
Augenklinik, Stadtspital Triemli, Birmensdorferstr. 497, 8063, Zürich, Schweiz,
Ophthalmologe. 2014 Feb;111(2):121-7. doi: 10.1007/s00347-013-2933-8.
A broad spectrum of anti-inflammatory drugs with different mechanisms is available for the treatment of intraocular inflammation. Corticosteroids are the mainstay of therapy. Mechanisms of action are quite well understood for most drugs in particular taken from animal research studies. However, pharmacokinetic evidence for treatment of ocular disease is generally limited for the human eye and especially for ocular inflammation. The bioavailability of a particular drug in an inflamed eye is expected to be faster due to a barrier breakdown. Therefore, intraocular level of effective substances should be lowered more rapidly than in a non-inflamed eye due to improved drainage. This article reviews current knowledge firstly about local, regional and systemic anti-inflammatory therapy of uveitis and finally on immuosuppressive systemic therapy.
有多种作用机制不同的抗炎药物可用于治疗眼内炎症。皮质类固醇是治疗的主要药物。大多数药物的作用机制,特别是从动物研究中得出的,已得到相当充分的了解。然而,对于人类眼睛,尤其是眼部炎症,治疗眼部疾病的药代动力学证据通常有限。由于屏障破坏,特定药物在发炎眼睛中的生物利用度预计会更快。因此,由于引流改善,有效物质的眼内水平应比未发炎的眼睛更快降低。本文首先综述了关于葡萄膜炎局部、区域和全身抗炎治疗的现有知识,最后综述了免疫抑制全身治疗。